Mauro Krampera

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 173 publications

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Journal: HemaSphere

Published: February 05, 2026

Dural Lymphomas Unmasked: A Narrative Review of Extra-Axial Mimics and a Pragmatic Diagnostic Decision Algorithm.

Dural Lymphomas Unmasked: A Narrative Review of Extra-Axial Mimics and a Pragmatic Diagnostic Decision Algorithm.

Journal: Cancers

Published: January 31, 2026

Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series.

Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series.

Journal: Annals of hematology

Published: January 07, 2026

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study.

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front-line hypomethylating agents and venetoclax: A retrospective Italian study.

Journal: British journal of haematology

Published: January 07, 2026

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease.

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease.

Journal: Hematological oncology

Published: November 18, 2025

Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network.

Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network.

Journal: Expert opinion on biological therapy

Published: October 31, 2025

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12.

Journal: Blood advances

Published: October 22, 2025

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Journal: Blood advances

Published: October 20, 2025

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study.

Journal: Transplantation and cellular therapy

Published: October 19, 2025

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 18, 2025

Fate and function of exogenously administered mesenchymal stromal cells: current insights and future directions.

Fate and function of exogenously administered mesenchymal stromal cells: current insights and future directions.

Journal: Cytotherapy

Published: September 13, 2025

Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment.

Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment.

Journal: Antibodies (Basel, Switzerland)

Published: August 11, 2025

Showing 1-12 of 173

Last Updated: 09/26/2026